UNSPSC 51322701: Mevastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C23H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UQM1K0W9X, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone but generally known as mevastatin, which bears US NIH Compound Identifier 53232. European Medicines Agency schedules Mevastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08927MIG.

UNSPSC 51322701 Mevastatin, a Commodity code, represents pharmaceutical supply procurement for emergency medical services and state health programs. State and local governments procure advanced life support medications and generic multi-source pharmaceuticals under this code through fire departments, health and human services agencies, and cooperative purchasing alliances. The scope encompasses sealed-bid supply contracts for specific medication line items (vials, injections, in defined quantities and strengths), direct-to-manufacturer prescription programs to bypass traditional pharmacy benefit managers, and framework agreements for generic and over-the-counter products distributed through authorized wholesalers. Vendors must meet manufacturing compliance standards including current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, FDA requirements, and provide safety documentation (Safety Data Sheets compliant with OSHA Hazard Communication Standards). Expiration-date requirements are standard — nine months or more from acceptance for emergency medications, and at least one year from manufacture for generic products. Procurement issuing bodies include city purchasing departments (Tampa), state health agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local facilities across multiple participating states).

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol HCI, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue with a response deadline of April 8, 2026, and an estimated contract value of $40,000, featuring a Small Local Business Enterprise (SLBE) sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription contracting without pharmacy benefit managers or group purchasing organizations. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with contract effectiveness on July 1, 2026.